Merck (MRK)
The desk's stance
On our research list, not on the slate.
What the company does
Keytruda is the ~$31B cancer franchise that powers half the company. With the 2028 IV patent cliff looming, Merck launched subcutaneous Keytruda Qlex (approved late 2025; $463M in Q2 2026) to rapidly transition patients to a 1-to-2-minute injection before generic erosion hits.
In short: Prescription pharmaceuticals and vaccines developer. Category: Mega-Cap Oncology & Biopharma. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $145.76, computed Oct 18, 2026 (confidence: medium).
How we got there: 50% analyst leg $145.76 (street consensus, after 8% optimism discount) + 50% GainStreet factor value $149.15 (16.05× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street. 4 analyst targets have no linked source and are shown but not counted; this value will not open a position until they are sourced.
G-Street Score: 53 out of 100 (Weak).
- Top-line growth & guidance: 10 of 32
- Margin power: 12 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 18 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 3 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Keytruda and Winrevair drive over $16B in annual FCF, funding extensive pipeline expansion.
- Subcutaneous Keytruda and antibody-drug conjugates provide commercial defense against upcoming 2028 patent expirations.
- Cardiopulmonary therapies and mRNA oncology programs offer substantial long-term top-line diversification.
Risks
- Keytruda generates over 45% of sales and faces US patent loss in 2028.
- Recent quarterly revenue trajectory is flat, while top-line growth trails faster peers like LLY.
- Seven recent negative EPS revisions reflect upfront business development charges pressuring near-term GAAP profitability.
What we're watching
- Q3 2026 earnings report and updated fiscal guidance scheduled for October 29, 2026.
- Commercial adoption trajectory and reimbursement coverage for Winrevair under permanent J-code billing.
- Phase 3 clinical trial readouts for Sac-TMT and mRNA personalized cancer vaccine data.
Latest
MRK trades at $145.95, hovering 7.0% below its 52-week high of $156.92 at 15.7x forward earnings after a 72.1% one-year advance. Trailing free cash flow remains exceptional at $16.06B, yet upfront licensing charges generated GAAP losses across H1 2026 and drove seven downward EPS revisions over the past month. Sequential top-line revenue has stabilized near $16.6B, with investor scrutiny centered on Q3 execution ahead of the October 29, 2026 release.
Key numbers
As of Oct 16, 2026: market cap $360.1B · revenue growth +5.1% year over year · gross margin 75.9% · net margin 4.8% · forward P/E 15.7 · next earnings Oct 29, 2026.
On the Gainz Lab maps
Who it does business with
- Merck partners with Moderna — Cancer-vaccine bet. Merck co-develops Moderna's individualized neoantigen therapy (intismeran autogene / mRNA-4157) with Keytruda in Phase 3 melanoma and NSCLC.
- Merck supplies The Patient — Keytruda & Qlex (about $31.0B a year). The premier cancer blockbuster transitioning patients to subcutaneous Keytruda Qlex ahead of 2028 IV patent expiry.